Home » Stocks » SEEL

Seelos Therapeutics, Inc. (SEEL)

Stock Price: $2.60 USD -0.06 (-2.26%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $2.70 +0.10 (3.85%) Mar 5, 7:55 PM
Market Cap 187.37M
Revenue (ttm) n/a
Net Income (ttm) -23.31M
Shares Out 46.99M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.60
Previous Close $2.66
Change ($) -0.06
Change (%) -2.26%
Day's Open 2.76
Day's Range 2.17 - 2.79
Day's Volume 3,250,517
52-Week Range 0.42 - 4.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 weeks ago

Seelos Therapeutics Inc (NASDAQ: SEEL) has amended the agreement with Vyera Pharmaceuticals AG, announced in March 2018, to develop SLS-002 to repurchase a significant portion of the royalties...

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

PRNewsWire - 1 month ago

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

PRNewsWire - 1 month ago

NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

Benzinga - 1 month ago

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S...

Other stocks mentioned: NVS, ALLO, SELB
PRNewsWire - 1 month ago

NEW YORK, Jan. 25, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

Benzinga - 1 month ago

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science ...

Other stocks mentioned: FLDM, ADMP, BCRX
PRNewsWire - 1 month ago

NEW YORK, Jan. 22, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

PRNewsWire - 1 month ago

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

PRNewsWire - 2 months ago

NEW YORK, Jan. 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system d...

PRNewsWire - 2 months ago

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

PRNewsWire - 2 months ago

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

PRNewsWire - 3 months ago

NEW YORK, Nov. 9, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system d...

PRNewsWire - 5 months ago

NEW YORK, Sept. 9, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

PRNewsWire - 6 months ago

NEW YORK, Sept. 4, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

PRNewsWire - 6 months ago

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

PRNewsWire - 7 months ago

NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

PRNewsWire - 7 months ago

NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

Forbes - 8 months ago

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify severa...

Other stocks mentioned: AGLE, DVAX, LQDA, PHAS
GlobeNewsWire - 8 months ago

SLS-002 Was Safe and Well Tolerated Across All Doses with Resolution of Expected Group Mean Dissociative Side-Effects That Occurred in the Higher Dose Groups Within One Hour Food and Drug Ad...

GlobeNewsWire - 8 months ago

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system di...

Benzinga - 9 months ago

Seelos Therapeutics (NASDAQ: SEEL) shares are trading higher on Thursday after the company announced the initiation of a preclinical study of SLS-004 In Parkinson's Disease.

GlobeNewsWire - 9 months ago

Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein

GlobeNewsWire - 9 months ago

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sy...

GlobeNewsWire - 9 months ago

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sy...

GlobeNewsWire - 10 months ago

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sy...

GlobeNewsWire - 10 months ago

NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...

GlobeNewsWire - 10 months ago

NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...

GlobeNewsWire - 11 months ago

Seelos Completed Type C Meeting with FDA to Discuss Trial Design for Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder Seelos Completed Type ...

GlobeNewsWire - 11 months ago

NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...

GlobeNewsWire - 11 months ago

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...

GlobeNewsWire - 11 months ago

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...

GlobeNewsWire - 11 months ago

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...

GlobeNewsWire - 1 year ago

Seelos Producing Viral Vectors and Preparing for In-Vivo Study in Parkinson's Disease Seelos Producing Viral Vectors and Preparing for In-Vivo Study in Parkinson's Disease

Seeking Alpha - 1 year ago

Jazz Pharma's Mixed Earnings, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: JAZZ, SUPN
GlobeNewsWire - 1 year ago

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

Preliminary Data Expected in the First Quarter of 2020 Preliminary Data Expected in the First Quarter of 2020

GlobeNewsWire - 1 year ago

Preliminary Data from Phase I DDI Study Expected in the First Quarter of 2020 Preliminary Data from Phase I DDI Study Expected in the First Quarter of 2020

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous s...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos c...

GlobeNewsWire - 1 year ago

Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive Disorder

About SEEL

Seelos Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for ... [Read more...]

Industry
Biotechnology
Founded
2016
CEO
Raj Mehra
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
SEEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for SEEL stock is "Buy." The 12-month stock price forecast is 8.00, which is an increase of 207.69% from the latest price.

Price Target
$8.00
(207.69% upside)
Analyst Consensus: Buy